Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8670-8678

  Worthmann, Hans ^a   Dengler, Reinhard ^a   Schumacher, Helmut ^b   Schwartz, Andreas ^c   Eisert, Wolfgang G ^a,d   Lichtinghagen, Ralf ^a   Weissenborn, Karin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Klinikum Hanover Nordstadt   (Germany)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Acetylsalicylic acid (ASA); Antithrombotic therapy; Dipyridamole; Ischemic stroke; Monocyte chemoattractant protein 1 (MCP 1); Neuroprotection

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OPEN STUDY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; BLOOD; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; STROKE; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CHEMOKINE CCL2; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STROKE; TIME FACTORS;

EID: 84864376967     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078670     Document Type: Article

References (24)

1. Mergenthaler, P.; Dirnagl, U.; Meisel, A. Pathophysiology of stroke: Lessons from animal models. Metab. Brain Dis. 2004, 19, 151-167.
2. Rodríguez-Yáñez, M.; Castillo, J. Role of inflammatory markers in brain ischemia. Curr. Opin. Neurol. 2008, 21, 353-357.
3. Worthmann, H.; Tryc, A.B.; Goldbecker, A.; Ma, Y.T.; Tountopoulou, A.; Hahn, A.; Dengler, R. Lichtinghagen, R.; Weissenborn, K. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis. 2010, 30, 85-92.
4. Welsh, P.; Barber, M.; Langhorne, P.; Rumley, A.; Lowe, G.D.; Stott, D.J. Associations of inflammatory biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 2009, 27, 247-253.
5. Foerch, C.; Montaner, J.; Furie, K.L.; Ning, M.M.; Lo, E.H. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 2009, 73, 393-399.
6. Chen, Y.; Hallenbeck, J.M.; Ruetzler, C.; Bol, D.; Thomas, K.; Berman, N.E.; Vogel, S.N. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab. 2003, 23, 748-755.
7. Justicia, C.; Panes, J.; Sole, S.; Cervera, A.; Deulofeu, R.; Chamorro, A.; Planas, A.M. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 2003, 23, 1430-1440.
8. Weyrich, A.S.; Denis, M.M.; Kuhlmann-Eyre, J.R.; Spencer, E.D.; Dixon, D.A.; Marathe, G.K. McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005, 111, 633-642.
9. Suzuki, S.; Sugai, K.; Sato, H.; Sakatume, M.; Arakawa, M. Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytes. Eur. J. Pharmacol. 1992, 227, 395-401.
10. Chakrabarti, S.; Vitseva, O.; Iyu, D.; Varghese, S.; Freedman, J.E. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J. Pharmacol. Exp. Ther. 2005, 315, 494-500.
11. Chakrabarti, S.; Freedman, J.E. Dipyridamole, cerebrovascular disease, and the vasculature. Vasc. Pharmacol. 2008, 48, 143-149.
12. Al-Bahrani, A.; Taha, S.; Shaath, H.; Bakhiet, M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr. Neurovasc. Res. 2007, 4, 31-37.
13. Hallevi, H.; Hazan-Halevy, I.; Paran, E. Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur. J. Neurol. 2007, 14, 1002-1007.
14. Offner, H.; Subramanian, S.; Parker, S.M.; Afentoulis, M.E.; Vandenbark, A.A.; Hurn, P.D. Experimental stroke induces massive, rapid activation of the peripheral immune system. J. Cereb. Blood Flow Metab. 2006, 26, 654-665.
15. Conductier, G.; Blondeau, N.; Guyon, A.; Nahon, J.L.; Rovère, C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J. Neuroimmunol. 2010, 224, 93-100.
16. Hughes, P.M.; Allegrini, P.R.; Rudin, M.; Perry, V.H.; Mir, A.K.; Wiessner, C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow Metab. 2002, 22, 308-317.
17. Strecker, J.K.; Minnerup, J.; Gess, B.; Ringelstein, E.B.; Schäbitz, W.R.; Schilling, M. Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice. PLoS One 2011, 6, e25863.
18. Dimitrijevic, O.B.; Stamatovic, S.M.; Keep, R.F.; Andjelkovic, A.V. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007, 38, 1345-1353.
19. Kim, H.H.; Liao, J.K. Translational therapeutics of dipyridamole. Arterioscler. Thromb. Vasc. Biol. 2008, 28, s39-s42.
20. Guo, S.; Stins, M.; Ning, M.; Lo, E.H. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc. Dis. 2010, 30, 290-296.
21. García-Bonilla, L.; Sosti, V.; Campos, M.; Penalba, A.; Boada, C.; Sumalla, M. Hernández-Guillamon, M.; Rosell, A.; Montaner, J. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res. 2011, 1373, 211-220.
22. Dengler, R.; Diener, H.C.; Schwartz, A.; Grond, M.; Schumacher, H.; Machnig, T. Eschenfelder, C.C.; Leonard, J.; Weissenborn, K.; Kastrup, A.; et al. EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): A randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010, 9, 159-166.
23. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. In Proceeding of 48th World Medical Association General Assembly, Somerset West, South Africa, 22-26 October 1996. Available online: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed on 1 May 2012.
24. Guideline for Good Clinical Practice E6(R1). International Conference on Harmonisation Harmonised Tripartite Guideline, 1996. Available online: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (accessed on 1 May 2012).